| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Prospective identification of tumorigenic breast cancer cells.
|
Proc Natl Acad Sci U S A
|
2003
|
59.17
|
|
2
|
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.
|
Nature
|
2006
|
27.91
|
|
3
|
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.
|
Lancet
|
2005
|
24.57
|
|
4
|
Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.
|
N Engl J Med
|
2002
|
18.61
|
|
5
|
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.
|
Nature
|
1993
|
15.70
|
|
6
|
Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer.
|
N Engl J Med
|
2002
|
12.83
|
|
7
|
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.
|
N Engl J Med
|
2001
|
11.73
|
|
8
|
Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.
|
Lancet
|
2001
|
6.24
|
|
9
|
Self-renewal and solid tumor stem cells.
|
Oncogene
|
2004
|
4.60
|
|
10
|
Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis.
|
J Clin Oncol
|
2006
|
3.77
|
|
11
|
Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects.
|
J Clin Invest
|
2002
|
3.24
|
|
12
|
Is cancer a disease of self-seeding?
|
Nat Med
|
2006
|
3.19
|
|
13
|
TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression.
|
J Clin Invest
|
2003
|
3.01
|
|
14
|
Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor.
|
Ann Surg Oncol
|
2006
|
2.84
|
|
15
|
Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988-2003 SEER data.
|
Ann Surg Oncol
|
2007
|
2.36
|
|
16
|
Does aggressive local therapy improve survival in metastatic breast cancer?
|
Surgery
|
2002
|
2.13
|
|
17
|
Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment.
|
J Clin Oncol
|
2000
|
1.68
|
|
18
|
Morbidity and mortality following breast cancer surgery in women: national benchmarks for standards of care.
|
Ann Surg
|
2007
|
1.57
|
|
19
|
Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor.
|
Ann Surg
|
1995
|
1.40
|
|
20
|
Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place.
|
J Urol
|
1999
|
1.07
|
|
21
|
Does local surgery have a role in the management of stage IV breast cancer?
|
Eur J Surg Oncol
|
2003
|
1.05
|
|
22
|
Preoperative core needle biopsy does not increase local recurrence rate in breast cancer patients.
|
Breast Cancer Res Treat
|
2006
|
1.03
|
|
23
|
A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation.
|
Br J Urol
|
1996
|
0.96
|
|
24
|
Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers.
|
Clin Breast Cancer
|
2003
|
0.95
|
|
25
|
Higher plasma vascular endothelial growth factor levels correlate with menopause, overexpression of p53, and recurrence of breast cancer.
|
Breast Cancer
|
2003
|
0.90
|
|
26
|
Primary metastatic breast cancer: the impact of locoregional therapy.
|
Breast Care (Basel)
|
2014
|
0.88
|
|
27
|
Changes in plasma vascular endothelial growth factor, angiopoietins, and their receptors following surgery for breast cancer.
|
Cancer Lett
|
2006
|
0.86
|
|
28
|
Does removal of the primary tumor in metastatic breast cancer improve survival?
|
J Womens Health (Larchmt)
|
2013
|
0.86
|
|
29
|
Systemic effects of surgery: quantitative analysis of circulating basic fibroblast growth factor (bFGF), Vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta) in patients with breast cancer who underwent limited or extended surgery.
|
Breast Cancer Res Treat
|
2005
|
0.82
|
|
30
|
Resection of the primary tumor in stage IV breast cancer.
|
World J Clin Oncol
|
2014
|
0.78
|
|
31
|
Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment.
|
Int J Oncol
|
2002
|
0.78
|
|
32
|
Changes in the circulating plasma levels of VEGF and VEGF-D after adjuvant chemotherapy in patients with breast cancer and 1 to 3 positive lymph nodes.
|
Anticancer Res
|
2006
|
0.77
|